Lixte (LIXT) director receives 15,000 RSUs equity grant

Rhea-AI Filing Summary

Primus Guy Warren reported acquisition or exercise transactions in this Form 4 filing.

Lixte Biotechnology Holdings director Guy Warren Primus received 15,000 restricted stock units (RSUs) as an equity award. The RSUs were granted under the company’s 2020 Stock Incentive Plan at no cash cost and vest upon achievement of performance conditions, which have already been satisfied.

After this award, Primus reports a total of 40,000 RSUs, including 25,000 previously granted RSUs that have vested. This is a compensation-related grant rather than an open-market share purchase or sale.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Primus Guy Warren

Role null

Type	Security	Shares	Price	Value
Grant/Award	Common Stock	15,000	$0.00	--

Holdings After Transaction: Common Stock — 40,000 shares (Direct, null)

Footnotes (1)

1. The reported transaction involved the Reporting Person's receipt of 15,000 restricted share units ("RSUs"). The RSUs were granted pursuant to the applicable RSU agreement and the Lixte Biotechnology Holdings, Inc. 2020 Stock Incentive Plan. Each RSU represents a contingent right to receive one share of common stock upon vesting, subject to continued service. The 15,000 RSUs vested upon the achievement of the performance conditions set forth in the Reporting Person's RSU agreement, which have been satisfied. The total reported in Column 5 includes (i) the 15,000 newly awarded RSUs, and (ii) 25,000 RSUs, all of which have vested.

Key Figures

RSUs granted: 15,000 RSUs Total RSUs after grant: 40,000 RSUs Previously vested RSUs: 25,000 RSUs +2 more

5 metrics

RSUs granted 15,000 RSUs Equity award reported on Form 4

Total RSUs after grant 40,000 RSUs Column 5 holding after transaction

Previously vested RSUs 25,000 RSUs RSUs that had already vested before new award

Grant price per RSU $0.00 per unit Reported transaction price on Form 4

Transaction date 2026-07-01 Date of RSU grant

Key Terms

restricted share units ("RSUs"), 2020 Stock Incentive Plan, contingent right to receive one share of common stock, performance conditions

4 terms

restricted share units ("RSUs") financial

"The reported transaction involved the Reporting Person's receipt of 15,000 restricted share units ("RSUs")."

2020 Stock Incentive Plan financial

"The RSUs were granted pursuant to the applicable RSU agreement and the Lixte Biotechnology Holdings, Inc. 2020 Stock Incentive Plan."

contingent right to receive one share of common stock financial

"Each RSU represents a contingent right to receive one share of common stock upon vesting, subject to continued service."

performance conditions financial

"The 15,000 RSUs vested upon the achievement of the performance conditions set forth in the Reporting Person's RSU agreement, which have been satisfied."

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

Available on EDGAR 07/02/2026 - 04:12 PM Accepted by SEC EDGAR 07/02/2026 - 04:11 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Primus Guy Warren

(Last) (First) (Middle)

433 PLAZA REAL, SUITE 275

(Street)

BOCA RATON FLORIDA 33432

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
LIXTE BIOTECHNOLOGY HOLDINGS, INC. [ LIXT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
07/01/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	07/01/2026		A		15,000(1)	A	$0	40,000(2)	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The reported transaction involved the Reporting Person's receipt of 15,000 restricted share units ("RSUs"). The RSUs were granted pursuant to the applicable RSU agreement and the Lixte Biotechnology Holdings, Inc. 2020 Stock Incentive Plan. Each RSU represents a contingent right to receive one share of common stock upon vesting, subject to continued service. The 15,000 RSUs vested upon the achievement of the performance conditions set forth in the Reporting Person's RSU agreement, which have been satisfied.

2. The total reported in Column 5 includes (i) the 15,000 newly awarded RSUs, and (ii) 25,000 RSUs, all of which have vested.

	/s/ Guy Primus	07/02/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What did LIXT director Guy Warren Primus report on this Form 4?

He reported receiving 15,000 restricted stock units (RSUs) as an equity award. The grant was made under Lixte’s 2020 Stock Incentive Plan and represents stock-based compensation, not an open-market purchase or sale of existing LIXT shares.

How many LIXT RSUs does Guy Warren Primus hold after this transaction?

After this grant, he reports 40,000 RSUs in total. This includes the 15,000 newly awarded RSUs plus 25,000 previously granted RSUs, all of which have vested according to the Form 4 footnote disclosure.

Were the 15,000 LIXT RSUs subject to performance conditions?

Yes. The 15,000 RSUs vested upon the achievement of performance conditions in Primus’s RSU agreement. The filing states these performance conditions have been satisfied, so the units have already vested as of the reported date.

Is this LIXT Form 4 a market buy or sell of common stock?

No, it reflects a grant of RSUs as compensation, not a market transaction. The award was made at a reported price of $0.00 per unit, indicating no cash was paid or received in the open market for these shares.

Under which plan were the new LIXT RSUs granted to the director?

The 15,000 RSUs were granted under the Lixte Biotechnology Holdings, Inc. 2020 Stock Incentive Plan. The grant is governed by an RSU agreement that specifies performance conditions and the contingent right to receive common shares upon vesting.